Item Regulation Furnished herewith as Exhibit 99.1 is a press release, dated May 14, 2026, related to a Virtual Investor Key Opinion Leader Connect segment (the “ Segment”) in which Professor Casper H. J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center and a consultant for AIM ImmunoTech Inc. (the “ Company”), and Thomas K. Equels, MS, JD, the Company’s Chief Executive Officer, participated. In addition, a video of the Segment was posted on the Virtual Investor website at https://virtualinvestorco. com/aim/. The information, including Exhibit 99.1 and the video Segment, referenced herein, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, if and to the extent such subsequent filing specifically references the information herein as being incorporated by reference in such filing. The information, including the Segment, on the website referenced above is not part of this Current Report on Form 8-K, and any references to such website or any other website are inactive textual references only.

Item Financial Exhibit Description No. 99.1 Press Release dated May 14, 2026. ─────────────────────────────────────────────────────────────────────────────────────── 104 Cover SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Dated: By: /s/ Thomas